Financial highlights:
-
Quarterly revenues of
$47.5 million , driven by strong manufacturing and royalty revenues from RISPERDAL® CONSTA®. Worldwide sales of RISPERDAL CONSTA by Janssen,Division of Ortho-McNeil-Janssen Pharmaceuticals , Inc. and Janssen-Cilag (Janssen) were approximately$348 million , an increase of 6.9 percent from the previous quarter and are based on product sales in approximately 60 countries. -
GAAP net loss of
$10.2 million and pro forma net income of$1.2 million . The GAAP net loss was driven primarily by$8.2 million of charges associated with the planned relocation of the company’s headquarters. -
Strong financial position, with cash and total investments of
$380.4 million .
Additional highlights:
- Positive data reported for DURATION-3 which demonstrated superiority of exenatide once weekly compared to LANTUS® (insulin glargine) in patients with type 2 diabetes.
-
New Drug Application (NDA) submission for exenatide once weekly
accepted by the
U.S. Food and Drug Administration (FDA ). -
RISPERDAL CONSTA launched in
Japan by Janssen Pharmaceutica K.K. for the treatment of schizophrenia. -
RISPERDAL CONSTA approved in the
European Union for use as a deltoid injection for the treatment of schizophrenia. RISPERDAL CONSTA was previously approved in the EU as a gluteal injection only.
“RISPERDAL CONSTA continues to serve as a platform for growth. We also
have a near-term opportunity to add a new revenue stream with royalties
from exenatide once weekly, with several major milestones accomplished
recently, including the acceptance of the NDA and positive data from the
DURATION-3 study,” commented
Key operating results for the quarter ended
-
GAAP net loss was
$10.2 million or a basic and diluted loss per share of$0.11 , including$3.2 million in share-based compensation expense and$8.2 million of charges associated with the relocation of the company’s headquarters. For the same period in 2008, net income was$29.7 million or a basic and diluted earnings per share of$0.31 , including$4.5 million in share-based compensation expense and$24.7 million of income, net of taxes, received fromEli Lilly and Company (Lilly) in conjunction with the AIR® Insulin program. -
Pro forma net income was
$1.2 million or a basic and diluted earnings per share of$0.01 , compared to a pro forma net income of$9.5 million or a basic and diluted earnings per share of$0.10 for the same period in 2008.
Pro Forma |
Impact of the |
Charges Related to |
Share-Based |
Reported GAAP |
||||||||||
Q1 FY 2010 | $0.01 | -- | ($0.09 | ) | ($0.03 | ) | ($0.11 | ) | ||||||
Q1 FY 2009 | $0.10 | $0.26 | -- | ($0.05 | ) | $0.31 |
Revenues
-
Total revenues for the quarter ended
June 30, 2009 , were$47.5 million , compared to$80.0 million for the same period in 2008. -
Total manufacturing revenues for the quarter ended
June 30, 2009 , were$28.8 million , which included$27.9 million related to RISPERDAL CONSTA, compared to$38.6 million , which included$36.0 million related to RISPERDAL CONSTA and$2.6 million related to VIVITROL, for the same period in 2008. -
Royalty revenues for the quarter ended
June 30, 2009 , were$8.7 million , based on RISPERDAL CONSTA sales of$347.8 million , compared to$8.6 million , based on RISPERDAL CONSTA sales of$343.1 million for the same period in 2008. -
Net sales from VIVITROL recorded by
Alkermes for the quarter endedJune 30, 2009 , were$4.2 million , compared to net sales of$4.1 million recorded byCephalon, Inc. for the same period in 2008. -
Research and development (R&D) revenue under collaborative
arrangements for the quarter ended
June 30, 2009 , was$1.5 million , compared to$31.4 million for the same period in 2008. -
Net collaborative profit for the quarter ended
June 30, 2009 , was$4.3 million , compared to$1.4 million for the same period in 2008.
Costs and Expenses
-
Cost of goods manufactured and sold for the quarter ended
June 30, 2009 , was$12.7 million , which included$9.7 million related to RISPERDAL CONSTA and$2.0 million related to VIVITROL, compared to$14.3 million for the same period in 2008, of which$10.8 million related to RISPERDAL CONSTA and$3.5 million related to VIVITROL. -
R&D expenses for the quarter ended
June 30, 2009 , were$25.6 million , which included$8.0 million of charges associated with the planned relocation of the company’s headquarters, primarily related to the accelerated depreciation of certain R&D-related assets. R&D expenses were$22.3 million for the same period in 2008. -
Selling, general and administrative (SG&A) expenses for the quarter
ended
June 30, 2009 , were$19.3 million , compared to$11.9 million for the same period in 2008. -
Share-based compensation expense (included in the expenses above) for
the quarter ended
June 30, 2009 , was$3.2 million , of which$0.3 million related to cost of goods manufactured,$0.8 million related to R&D expenses and$2.1 million related to SG&A expenses. Share-based compensation expense for the same period in 2008 was$4.5 million , of which$0.4 million related to cost of goods manufactured,$1.6 million related to R&D expenses and$2.5 million related to SG&A expenses. -
Interest income for the quarter ended
June 30, 2009 , was$1.6 million , compared to$3.6 million for the same period in 2008. Interest expense for the quarter endedJune 30, 2009 , was$1.7 million , compared to$4.2 million for the same period in 2008. -
Income tax benefit for the quarter ended
June 30, 2009 , was$0.1 million , compared to an income tax expense of$1.0 million for the same period in 2008.
At
Conference Call
About
Certain statements set forth above may constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to: statements concerning
future business and operating results; the successful manufacture and
commercialization of VIVITROL and RISPERDAL CONSTA; continued revenue
growth from RISPERDAL CONSTA; the superiority of exenatide once weekly
over LANTUS in real-world use; and the successful continuation of
development activities for the company's programs. Although the company
believes that such statements are based on reasonable assumptions within
the bounds of its knowledge of its business and operations, the
forward-looking statements are neither promises nor guarantees and the
company's business is subject to significant risk and uncertainties, and
there can be no assurance that its actual results will not differ
materially from its expectations. These risks and uncertainties include,
among others: whether the company will achieve the financial
expectations provided; whether the company can continue to manufacture
RISPERDAL CONSTA and VIVITROL on a commercial scale, economically or in
sufficient quantities to supply the market; whether VIVITROL will be
commercialized successfully by
VIVITROL® and AIR® are registered trademarks of
(tables follow)
Alkermes, Inc. and Subsidiaries | ||||||
Selected Financial Information (Unaudited) | ||||||
Three Months | Three Months | |||||
Ended | Ended | |||||
Condensed Consolidated Statements of Operations | June 30, | June 30, | ||||
(In thousands, except per share data) | 2009 | 2008 | ||||
Revenues: | ||||||
Manufacturing revenues | $ 28,804 | $ 38,610 | ||||
Royalty revenues | 8,701 | 8,581 | ||||
Product sales, net | 4,226 | - | ||||
Research and development revenue under collaborative arrangements | 1,450 | 31,450 | ||||
Net collaborative profit | 4,315 | 1,351 | ||||
Total Revenues | 47,496 | 79,992 | ||||
Expenses: | ||||||
Cost of goods manufactured and sold | 12,666 | 14,314 | ||||
Research and development | 25,586 | 22,261 | ||||
Selling, general and administrative | 19,268 | 11,926 | ||||
Total Expenses | 57,520 | 48,501 | ||||
Operating (Loss) Income | (10,024 | ) | 31,491 | |||
Other Expense, net: | ||||||
Interest income | 1,561 | 3,616 | ||||
Interest expense | (1,709 | ) | (4,226 | ) | ||
Other expense, net | (63 | ) | (164 | ) | ||
Total Other Expense, net | (211 | ) | (774 | ) | ||
(Loss) Income Before Income Taxes | (10,235 | ) | 30,717 | |||
(Benefit) Provision for Income Taxes | (70 | ) | 1,030 | |||
Net (Loss) Income | $ (10,165 | ) | $ 29,687 | |||
(Loss) Earnings per Common Share: | ||||||
Basic | $ (0.11 | ) | $ 0.31 | |||
Diluted | $ (0.11 | ) | $ 0.31 | |||
Weighted Average Number of Common Shares Outstanding (GAAP): | ||||||
Basic | 94,883 | 95,361 | ||||
Diluted | 94,883 | 96,631 | ||||
Pro Forma Reconciliation: | ||||||
Net (Loss) Income - GAAP | $ (10,165 | ) | $ 29,687 | |||
Share-based compensation expense | 3,230 | 4,495 | ||||
Costs incurred related to the move of corporate headquarters | 8,171 | - | ||||
Income from Lilly related to termination of the AIR® Insulin program (net of income taxes) | - | (24,709 | ) | |||
Net Income - Pro Forma | $ 1,236 | $ 9,473 | ||||
Pro Forma Earnings per Common Share: | ||||||
Basic | $ 0.01 | $ 0.10 | ||||
Diluted | $ 0.01 | $ 0.10 | ||||
Weighted Average Number of Common Shares Outstanding (Pro Forma): | ||||||
Basic | 94,883 | 95,361 | ||||
Diluted | 95,462 | 96,631 | ||||
Condensed Consolidated Balance Sheets | June 30, | March 31, | ||||
(In thousands) | 2009 | 2009 | ||||
Cash, cash equivalents and total investments | $ 380,419 | $ 404,482 | ||||
Receivables | 27,899 | 24,588 | ||||
Inventory | 20,528 | 20,297 | ||||
Prepaid expenses and other current assets | 5,403 | 7,500 | ||||
Property, plant and equipment, net | 97,520 | 106,461 | ||||
Other assets | 3,442 | 3,158 | ||||
Total Assets | $ 535,211 | $ 566,486 | ||||
Non-recourse RISPERDAL CONSTA secured 7% notes - current | $ 25,667 | $ 25,667 | ||||
Other current liabilities | 26,570 | 43,323 | ||||
Non-recourse RISPERDAL CONSTA secured 7% notes - long-term | 44,057 | 50,221 | ||||
Deferred revenue - long-term | 5,204 | 5,238 | ||||
Other long-term liabilities | 6,846 | 7,149 | ||||
Total shareholders' equity | 426,867 | 434,888 | ||||
Total Liabilities and Shareholders' Equity | $ 535,211 | $ 566,486 | ||||
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the company's Annual Report on Form 10-K for the year ended March 31, 2009, and the company's report on Form 10-Q for the three months ended June 30, 2009, which the company intends to file in August 2009. |
Source:
Alkermes, Inc.
For Investors:
Rebecca Peterson, 617-583-6378
or
For
Media:
Jennifer Snyder, 617-583-6166